Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Chronic nAMD With Cataract Complications: Visual Stabilization Through Sequential Anti-VEGF Strategies | Ophthalmology Times
Treatment-Resistant Retinal Disease Management With Sequential Anti-VEGF Strategies This comprehensive presentation examines complex retinal disease management using sequential anti-VEGF therapies, supported by pharmacokinetic modeling from 17 aflibercept trials involving 2700 individuals. The data demonstrates that aflibercept 8 mg exhibits 34.4%…
DME Management With Transition to High-Dose Aflibercept Following Suboptimal Response to Standard Anti-VEGF Therapy | Ophthalmology Times
DME Management With High-Dose Aflibercept Summary This presentation discusses DME management, focusing on transitioning to high-dose aflibercept following suboptimal responses to standard anti-VEGF therapy. The session was part of a Case-Based Roundtable meeting held in conjunction with the American Society…
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…
Researchers assess atropine and cyclopentolate for detecting premyopia in young children | Ophthalmology Times
(Image Credit: AdobeStock) A comparison of 2 cycloplegic agents, atropine and cyclopentolate, in preschool children for cycloplegia found that atropine was associated with less myopic refraction compared with cyclopentolate and may potentially avoid the overestimation of premyopia prevalence,1 reported first…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD, PhD, introduced the Fight Retinal Blindness! Project, a comprehensive registry tracking VEGF inhibitor eye injection outcomes since 2007. Spanning 20 countries with 150 active practitioners, the project uniquely…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of its portfolio company, VISUfarma, a Netherlands-headquartered specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin. \n\n\n\n VISUfarma was created by GHO Capital in 2016 by combining…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting Harvey Uy, MD, DPBO, FVRDP, a retina specialist from the Peregrine Eye and Laser Institute in the Philippines, discussed the transformative power of digital image management in ophthalmology.…
Q&A: Prem S. Subramanian, MD, PhD, on neuro-ophthalmic insights at EyeCon 2025 | Ophthalmology Times
Prem S. Subramanian, MD, PhD, emphasized the importance of pattern recognition in distinguishing ocular from neurologic causes of visual symptoms during EyeCon 2025. (Image credit: AdobeStock/ryandi) “Pattern recognition is key,” emphasized Prem S. Subramanian, MD, PhD, as he discussed the…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the Eye Care Network, Marion Munk, MD, PhD, details a promising phase 2a clinical study of ISTH0036, an oligonucleotide antisense drug targeting TGF-β2. Developed to address fibrosis in neovascular…